Publications by authors named "F Franchi"
Antiplatelet therapy involving aspirin and a P2Y receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns. Although it occurs often, the optimal method for switching remains a concern owing to potential drug interactions, which can result in either inadequate platelet inhibition and subsequent thrombotic events or low platelet reactivity and increased bleeding risks due to therapy overlap.
View Article and Find Full Text PDFA paradigmatic case is presented of subarachnoid hemorrhage as the initial sign of bacterial endocarditis on a mechanical cardiac prosthesis, in the absence of symptoms and echocardiographic evidence of infective endocarditis and vegetation. The presentation emphasizes the need to pursue a diagnostic workup for bacterial endocarditis whenever a patient with a mechanical prosthesis presents to the emergency department with focal neurologic signs. In addition, it highlights the potential use of second-level diagnostic tools to assess the extent of abscess presence and lesion extension to other cardiac structures for proper surgical planning.
View Article and Find Full Text PDFCurrent evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFIntroduction: In critically ill patients, individualised strategies for red blood cell transfusion (RBCT) are lacking. The objective of this study is to demonstrate the potential advantages of employing an individualised transfusion strategy compared with a restrictive approach, in unselected intensive care unit (ICU) patients.
Methods: This will be a randomised, multicentre, international trial.
Switching from cangrelor to oral P2Y inhibitors: a focused review on drug-drug interactions.
Expert Opin Drug Metab Toxicol
October 2024
Article Synopsis
- Cangrelor is an intravenous medication that inhibits platelet P2Y receptors, effectively preventing blood clots during procedures like coronary interventions, especially in patients not on oral P2Y inhibitors.
- Its rapid platelet inhibition raises concerns about potential drug-drug interactions (DDIs) when switching to oral P2Y inhibitors, which is critical for patient safety.
- Proper timing during the transition to oral P2Y inhibitors, particularly clopidogrel and prasugrel, is crucial to minimize DDI risks, and following existing guidelines can enhance treatment outcomes.